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In vivo efficacy of endothelial growth 
medium stimulated mesenchymal stem cells 
derived from patients with critical limb ischemia
Rida Al‑Rifai1, Philippe Nguyen1,2, Nicole Bouland3, Christine Terryn4, Lukshe Kanagaratnam5, Gaël Poitevin1, 
Caroline François1, Catherine Boisson‑Vidal6,7, Marie‑Antoinette Sevestre8 and Claire Tournois1,2* 
Abstract 
Background: Cell therapy has been proposed for patients with critical limb ischemia (CLI). Autologous bone marrow 
derived cells (BMCs) have been mostly used, mesenchymal stem cells (MSCs) being an alternative. The aim of this 
study was to characterize two types of MSCs and evaluate their efficacy.
Methods: MSCs were obtained from CLI‑patients BMCs. Stimulated‑ (S‑) MSCs were cultured in endothelial growth 
medium. Cells were characterized by the expression of cell surface markers, the relative expression of 6 genes, the 
secretion of 10 cytokines and the ability to form vessel‑like structures. The cell proangiogenic properties was analysed 
in vivo, in a hindlimb ischemia model. Perfusion of lower limbs and functional tests were assessed for 28 days after cell 
infusion. Muscle histological analysis (neoangiogenesis, arteriogenesis and muscle repair) was performed.
Results: S‑MSCs can be obtained from CLI‑patients BMCs. They do not express endothelial specific markers but can 
be distinguished from MSCs by their secretome. S‑MSCs have the ability to form tube‑like structures and, in vivo, to 
induce blood flow recovery. No amputation was observed in S‑MSCs treated mice. Functional tests showed improve‑
ment in treated groups with a superiority of MSCs and S‑MSCs. In muscles, CD31+ and αSMA+ labelling were the 
highest in S‑MSCs treated mice. S‑MSCs induced the highest muscle repair.
Conclusions: S‑MSCs exert angiogenic potential probably mediated by a paracrine mechanism. Their administration 
is associated with flow recovery, limb salvage and muscle repair. The secretome from S‑MSCs or secretome‑derived 
products may have a strong potential in vessel regeneration and muscle repair.
Trial registration NCT00533104
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Background
Critical limb ischemia (CLI) is the most severe form of 
atherosclerotic peripheral arterial disease (PAD). Due to 
the progression of vascular risk factors, PAD incidence 
is predicted to double by 2050 [1]. The management of 
patients is limited to surgical revascularization. However, 
around up to 30% of patients are not eligible for such pro-
cedures due to poor distal vascular bed. Therefore, these 
“no-option” patients (NO-CLI) experience a high risk of 
major amputation [2] and are exposed to a high level of 
cardiovascular death [3].
In such context, cell therapy (CT) has been proposed 
for NO-CLI patients to promote angiogenesis and 
improve tissue perfusion [4]. To date over 120 phase I/
II or III clinical trials have investigated a variety of cell 
therapies [5]. Recent meta-analysis [6] are in favor of 
a clinical improvement of treated patients but results 
remain divided [7, 8]. In most cases, non-selected 
autologous bone marrow derived cells (BMCs) were 
used. They were obtained from elderly ill patients and 
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exhibit low proangiogenic potential [9]. In most studies 
BMCs were not well characterized.
We recently published a multicenter clinical trial 
evaluating the effect of autologous BMCs versus pla-
cebo in CLI-patients [Bone Marrow Autograft in Limb 
Ischemia (BALI)]. This study was in favor of efficacy 
but the rate of amputation remained elevated in treated 
patients [10]. Inflammation was associated with poor 
outcome [11]. In order to improve our understanding, 
BMCs were extensively characterized and we observed 
a great variability in BMCs composition between 
patients [11].
BMCs contained mature and immature cells [hemat-
opoietic stem cells (HSCs), endothelial progenitor 
cells]. Interestingly, they also contained a rare subset 
of mesenchymal stem cells (MSCs). These non-hemat-
opoietic mononuclear cells reside in the bone marrow 
(BM) stroma [12]. MSCs can be obtained in adults from 
many tissues such as adipose tissue (ADSCs), periph-
eral blood, synovial membrane and dental pulp. Fetal/
neonatal tissues [e.g., umbilical cord blood, umbilical 
cord Wharton’s jelly (WJ-MSCs), amniotic fluid, pla-
centa] are also a potential source of MSCs [13]. Still, 
human BM remains the main source of MSCs. They 
show an extensive capacity of differentiation into osteo-
blasts, chondrocytes, adipocytes, astrocytes and skel-
etal muscle cells [14]. MSCs can migrate, proliferate 
in areas of ischemia and can promote regeneration of 
damaged tissues and reducing inflammation [15]. They 
may be good candidates for CT as they combine proan-
giogenic, anti-inflammatory and immunomodulatory 
properties [16].
CT protocols in CLI-generally require hundreds of mil-
lions of MSCs per treatment [17–19]. Therefore, in vitro 
cell expansion is needed. In autologous situation, the 
patient’s age and clinical characteristics influence the 
culture efficiency [20]. Major efforts have been made to 
improve culture conditions and favor endothelial induc-
tion by adding supplements containing pro-angiogenic 
factors [vascular endothelial growth factor (VEGF), epi-
dermal growth factor (EGF), fibroblast growth factor-2 
(FGF2) and insulin-like growth factor-1 (IGF-1)] [21–27]. 
The so called “endothelial cell-specific growth medium” 
(EGM-2) improves the proliferation rate and may induce 
the acquisition of endothelial markers. These stimulated-
MSCs (S-MSCs) can form functional blood vessels in 
collagen-plug implanted in mice [21] but have never been 
tested in a hind limb ischemia model (HLIM).
The purpose of this study was: (1) to evaluate the pres-
ence of MSCs in CLI-patients BMCs, (2) to analyze the 
phenotype of S-MSCs, and (3) to compare the effect of 
MSCs and S-MSCs in a murine HLIM in comparison 
with BMCs.
Methods
Source and characterization of BMCs
BMCs were obtained from CLI patients included in the 
BALI multicenter trial (trial number NCT00533104). 
The study protocol was approved by the French National 
Agency for Medicines and Health Products Safety and by 
an Institutional Review Board. As previously described 
[10], 500  mL of BM were collected under general anes-
thesia through multiple punctures of the posterior iliac 
crest. BMCs were isolated using a blood cell separa-
tor (Cobe Spectra, version 4, BM Processing Program, 
Gambro BCT, Lakewood, CO, USA) and concentrated 
to obtain a final volume of 40 mL (30 mL for autologous 
injection and 10 mL for control analyses and cryopreser-
vation). BMCs were cryopreserved in liquid nitrogen in 
dimethyl sulfoxide as a cryoprotector.
The present study is as an ancillary study of BALI. 
BMCs were exclusively provided by the centers of Reims 
and Amiens (out of 9 centers) as they used similar meth-
ods of cell preparation, preservation and storage. Seven 
CLI-BMCs were selected regardless of patients’ charac-
teristics or clinical outcome.
BMCs were extensively characterized. For this, plate-
lets (PLTs) and nucleated cells counts were performed 
with an Advia 2120 automated counter (Siemens, Health 
care SAS, Saint-Denis, France). Cell morphology was 
observed after cytocentrifugation and May Grünwald 
Giemsa staining (Fig.  2a). CD34+ stem cell analysis 
was performed by flow cytometry (FC) according to the 
ISHAGE (International Society of Hematotherapy and 
Graft Engineering) reference method using Stem-Kit 
reagents (Beckman Coulter, Villepinte, France). Sam-
ples were analyzed on a Navios flow cytometer (Beck-
man Coulter). The MesenCult Proliferation Kit (Stemcell 
Technologies, Grenoble, France) was used for the fibro-
blast colony-forming units (CFU-F) assay.
Isolation of BM‑MSCs and cell culture
MSCs were obtained from 7 CLI cryopreserved BMCs. 
After thawing, cells were counted, and viability was eval-
uated. MSCs were selected by their capacity to adhere 
to uncoated plastic plates, cultured and expanded in a 
CFU-F medium (MesenCult™ Proliferation Kit, Stemcell 
Technologies) supplemented with 1% penicillin–strep-
tomycin–amphotericin (Antibiotic–Antimycotic 100X, 
Gibco by Life Technologies, Illkirch, France). Cells were 
cultured in a humidified incubator at 37  °C under a 5% 
 CO2 atmosphere. The culture was maintained through 
28 days (Fig. 1a).
S-MSCs were obtained from 7 CLI-MSCs after trypsi-
nization at day 14, and subsequent culture during another 
period of 14  days in a Endothelial growth medium 
(EGM)-2 comprised endothelial basal medium (EBM)-2 
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supplemented with SingleQuots Bulle-kit (Lonza, Basel, 
Switzerland) (0.5 ng/mL human VEGF, 5 ng/mL human 
EGF, 10  ng/mL human FGF2, 20  ng/mL long R3-insu-
lin-like growth factor-1, 22.5  µg/mL heparin, 1  µg/mL 
ascorbic acid, 0.2  µg/mL hydrocortisone) supplemented 
with 1% penicillin–streptomycin–amphotericin (Antibi-
otic–Antimycotic 100X, Gibco). Cells were cultured in 
a humidified incubator at 37 °C under a 5%  CO2 atmos-
phere (Fig. 1a).
Culture media were changed every 3 or 4 days. MSCs 
and S-MSCs were observed in phase contrast micros-
copy (Olympus, Plateforme en Imagerie Cellulaire et Tis-
sulaire PICT). Before injection, cells were washed twice 
in Phosphate Buffer Saline (PBS) (ET330, Euromedex, 
Souffelweyersheim, France), then counted. Viability was 
determined by Trypan blue and was above 90 ± 6%. Cells 
were resuspended in PBS.
Characterization of MSCs and S‑MSCs
Transcriptomic characterization of MSCs, S‑MSCs 
and cb‑ECFCs by simultaneous real‑time qPCR reactions
Gene expression analysis was performed at day 28, on 
both MSCs (n = 7) and S-MSCs (n = 7). Cord blood 
endothelial colony-forming cells (cb-ECFCs, n = 5) were 
used as control. Isolation and characterization of cb-
ECFC were performed as previously described [28]. Total 
RNA was extracted from 5 ×  106 cells, using the RNe-
asy Mini kit (Qiagen, Courtaboeuf, France). RNA was 
treated to eliminate any DNA contamination (Qiagen) 
and the quality of mRNA was assessed using the Expe-
rion automated electrophoresis system (Bio-Rad, Marnes 
La Coquette, France). Complementary DNA was synthe-
sized using the high-capacity cDNA reverse transcriptase 
(RT) kit with RNase inhibitor  (RT2 HT First Strand Kit, 
Qiagen). PCR primers targeting von Willebrand factor 
(vWF)(NM_000552.3), platelet endothelial cell adhe-
sion molecule 1 (PECAM1)(NM_000442.4), vascular 
endothelial growth factor receptor 2 (VEGF R2 or KDR)
(NM_002253.2), Ve-Cadherin (CDH5)(NM_001795.3), 
CXC motif receptor 4 (CXCR4)(NM_003467.2), vascu-
lar cell adhesion molecule 1 (VCAM1)(NM_001078.3), 
beta-2 microglobulin (B2M)(NM_004048), hypoxantine 
phosphoribosyltransferase-1 (HPRT1) (NM_000194) and 
glyceraldehyde-3-phosphate-dehydrogenase (GAPDH)
(NM_002046) were obtained from Qiagen (RNA QC 
PCR Array Qiagen). B2  M, HPRT1 and GAPDH were 
Fig. 1 Study design. a BMCs were obtained from 7 CLI patients. MSCs were selected and expanded in a CFU‑F medium for 28 days (n = 7). 
Stimulated MSCs were cultured in EGM‑2 medium for 14 days (n = 7). b Hindlimb ischemia was induced by femoral artery ligation in Nude mice. 
Cells (BMCs, MSCs, S‑MSCs) or vehicle were injected in the gastrocnemius. Hindlimb perfusion, Necrose detection and functional tests were 
performed during 28 days. At day 28 muscles were harvested for biological analysis
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used as housekeeping genes. Conventional PCR was 
performed under standard conditions  (RT2 SYBR Green 
ROX qPCR, Qiagen) and analyzed on the ABI 7500 
FAST-Real Time PCR System (Thermo Fisher Scientific, 
Courtaboeuf, France). Assays were systematically run in 
duplicate for each type of cells and for internal controls 
(human genomic DNA contamination, reverse transcrip-
tion control and positive PCR control). The mRNA levels 
of vWF, PECAM1, VEGF R2, Ve-Cadherin, CXCR4 and 
VCAM1 were normalized to housekeeping genes using 
the  2−ΔCt method (= 2−[Ct(target) − Ct(housekeeping gene)]).
Flow cytometry analysis
A four-color FC analysis was performed on FC500 ana-
lyzer (Beckman Coulter) to characterize MSCs and 
S-MSCs at day 28: FITC-conjugated CD105 (endoglin), 
CD31 (PECAM1) antibodies and PE-conjugated CD90 
(Thy-1), CD140a (Platelet-derived growth factor recep-
tor alpha, PDGF RA), CD140b (Platelet-derived growth 
factor receptor beta, PDGF RB), CD144 (Ve-Cadherin, 
CDH5), VEGF R1 (Vascular endothelial growth factor 
receptor 1, FLT1) antibodies and PE-Cy5-conjugated 
HLA-DR (human leukocyte antigen-D related), CD34, 
CD45, CD11b (integrin alpha M), CD146 (Melanoma 
adhesion molecule, MCAM), CD184 (CXCR4), CD106 
(VCAM1) antibodies and PE-Cy7 conjugated CD73 (5′ 
nucleotidase) and VEGF R2 (KDR, CD309) antibod-
ies. Mouse anti-Human CD105, CD90, CD73, HLA-
DR, CD140a, CD31, CD184, CD106 were obtained 
from BD Biosciences (Le Pont de Claix, France), CD34, 
CD45, CD11b, CD146, VEGFR2 from Beckman Coulter, 
CD140a, VEGFR1 from R&D Systems Inc (Minneapolis, 
USA) and CD144 from Santa-Cruz Biotechnology inc 
SCBT (Dallas, USA). The isotype-matched mouse IgG1-
FITC, IgG1-PE, IgG1-PCy5 and IgG1-PCy7 were used as 
negative controls. Acquisition and processing data from 
7,000 events were analysed using Kaluza software.
Cell secretome
Cell secretome was characterized by the quantification of 
growth factors productions and by their capacity to form 
tube-like structures.
Preparation of MSCs‑ and S‑MSCs‑derived conditioned 
medium
Culture media (CFU-F and EGM-2) had been changed at 
day 24. Aliquots of the CFU-F and EGM-2 media free of 
cells were placed in a humidified incubator at 37 °C under 
a 5%  CO2 atmosphere during 4  days. MSCs (n = 7) and 
S-MSCs (n = 7) culture supernates and cell-free media 
(CFU-F and EGM-2) were recovered at day 28, centri-
fuged at 300g for 5 min, filtered through a 0.22 µm and 
were then aliquoted and stored frozen at −  40  °C until 
use.
Growth factors assays
A set of ten growth factors [VEGF-A, EGF, FGF2, IGF-
1, Angiopoietin-1 (Angio-1), Interleukin-6 (IL-6), HGF, 
Platelet-derived growth factor alpha polypeptide (PDGF-
AA), Leukemia-inhibitory Factor (LIF), Chemokine CXC 
motif Ligand 12 (CXCL12 or Stromal-cell-derived fac-
tor-1, SDF-1)] was measured in the MSCs and S-MSCs 
culture supernates at day 28. Quantitative determina-
tion of IGF-1 concentrations was performed using the 
Quantikine ELISA kit (R&D Systems Inc). The 9-plex 
LEGENDplex panel is a bead-based multiplex assay 
panel, using fluorescence–encoded beads suitable for 
use on LSRFortessa (BD Biosciences). This panel allows 
the simultaneous quantification of 9 human cytokines 
(VEGF-A, EGF, FGF2, Angio-1, IL-6, HGF, PDGF-AA, 
LIF, CXCL12) (BioLegend Ozyme, Saint Quentin en Yve-
lines, France) (Plateau technique de Cytometrie en flux 
URCACyt). The Bradford Protein assay (Quick Start™ 
Bradford 1× Dye Reagent, Bio-Rad) was used to meas-
ure protein quantification in MSCs and S-MSCs culture 
supernates and in 2 media (CFU-F and EGM-2).
Tube formation assay
In order to assess the angiogenic effect of culture super-
nates, an in vitro assay was performed evaluating tubule 
formation from HMEC-1 endothelial cell line (Der-
mal microvascular endothelium, ATCC CRL-3243) 
[29]. HMEC-1 cells (8000 cells/well) were suspended in 
Endothelial Cell Basal medium MV (n = 3) (10  ng/mL 
EGF, 1  µg/mL hydrocortisone, 10  mM Glutamine, and 
10% FBS) (PromoCell, Heidelberg, Germany), or in cell-
free media [CFU-F (n = 3), or EGM-2 (n = 3)] or in MSCs 
culture supernates (obtained from 5 CLI-MSCs, n = 2 
each group), or in S-MSCs culture supernates (obtained 
from 5 CLI-S-MSCs, n = 2 each group), laid upon 
Matrigel (BD Biosciences, Le Pont de Claix, France) cast 
in IBIDI micro wells (81,501, µ-Slide Angiogenesis, Bio-
valley), and allowed to form tubules for 24 h under nor-
moxic conditions. Slides were observed during 24 h with 
a videomicroscope (Axiovert, 200  M, Zeiss, Germany) 
piloted by Software Metamorph (Roper Scientific). Pic-
tures were catched each 15 min (coolsnap HQ, Roper Sci-
entific, France). The capillary-like tubes were appreciated 
at 3:30 h by the quantification of the loops number and 
total tube length using the ImageJ software and Neuron-J 
plug in tool.
Cell functional assay: in vitro tube formation assay
Capillary-like tube formation was evaluated in a Matrigel 
(BD Biosciences) matrix. A volume of 10 µL of gel was 
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deposited on the uncoated slide (81,501, µ-Slide Angio-
genesis, Biovalley). After 30  min at 37  °C, a gel was 
formed and  104 cells (MSCs, S-MSCs, MRC and cb-
ECFC) were deposited. The extend of the network of the 
capillary-like tubes was appreciated at the time of maxi-
mal network (as indicated on Additional file  1: Figure 
S1) by the quantification of the loops number using the 
ImageJ software and Neuron-J plug in tool. MRC5 fibro-
blasts cells line (ATCC CCL-171; RD-Biotech, Besançon, 
France) was used as negative control. cb-ECFC were used 
as positive control.
Animal study
Study design
The aim of the study was to evaluate the efficacy of 
BMCs, MSCs and S-MSCs from CLI patients in com-
parison with vehicle in a murine HLIM (Fig. 1b). BALB/c 
Nude mice were included in the study. Hindlimb perfu-
sion and functional tests were assessed at baseline (day-
1). At day 0 hindlimb ischemia was induced after left 
common femoral artery ligation. Blood flow of the lower 
limbs was performed postoperatively. Viable cells [BMCs 
or MSCs or S-MSCs) or vehicle (PBS)] were injected in 
the left gastrocnemius muscle 4  h after ischemia induc-
tion. Blood flow measurement was considered as primary 
endpoint whereas necrosis detection and functional tests 
(static and dynamic) were considered as secondary end-
points. They were evaluated at days 1, 3, 5, 7, 10, 15, 20 
and 28 postoperatively. At day 28 gastrocnemius and sem-
imembranosus muscles were harvested for immunohisto-
logical analyses (Fig. 1b).
Murine hindlimb ischemia model and cell transplantation
One hundred and thirty-five male BALB/c Nude mice 
(Charles River Laboratories, l’Arbresle, France), 11 weeks 
of age were used for all experiments. They had access 
to water and food ad  libitum. Hindlimb ischemia was 
induced after the surgical left common femoral artery 
ligation [30]. Animals were placed on a 38 °C heating pad 
and anesthetized by continuous inhalation of isoflurane 
(5% in induction and 2% during the intervention). Expo-
sure was obtained by performing an incision in the skin 
overlying the high portion of the left hindlimb next to the 
inguinal ligament. The common left femoral artery was 
ligated with a non-absorbable 6.0 silk thread. Then the 
skin was closed with absorbable sutures. Buprenorphine 
was administered as analgesic (0.05  mg/kg twice a day 
for 3 days). Under anesthesia, mice were transplanted in 
their left gastrocnemius 4  h after surgery with 30 µL of 
PBS (n = 20 mice) or with 30 µL of 5 × 105 BMCs (n = 40 
mice and approximately 6 per condition) or of 5 ×  105 
MSCs (n = 35 mice and approximately 6 per condition) 
or of 5  ×  105 S-MSCs (n = 40 mice and approximately 
6 per condition). The quantity of injected cells (5 × 105) 
can be considered as low in comparison with similar pre-
viously published studies [31–33]. A 30-gauge needle was 
used for the unique intramuscular injection.
Blood flow analysis
Perfusion of lower limbs was assessed with  PeriCam® 
perfusion imaging  (PeriCam® PSI, Perimed, Craponne, 
France) at baseline and for 28  days after ligation. The 
Pericam perfusion imaging was able to quantify the blood 
flow in the microcirculation (arterioles, capillaries and 
veins) and the laser speckle contrast analysis (LASCA) 
facilitated high resolution and real-time visualization. 
Measures were taken under anesthesia with isoflurane 
and on a 38  °C heating pad. Low or no blood perfusion 
was displayed as dark blue, whereas the highest perfu-
sion was displayed as red. After blood flow was scanned 
during 30 s, stored records were analyzed with  PimSoft® 
software and the average flows of ischemic and non-
ischemic limbs were quantified. Ratios of the ischemic 
(left)/normal (right) limb blood flow were used to express 
the results. The mean and the standard deviation were 
used per group.
Clinical recovery
Necrosis detection Limb ischemia was assessed with the 
daily observation of mouse limbs searching for nail, toe, 
foot and leg necrosis or amputation.
Two functional tests (static and dynamic) were used to 
quantify post-ligature clinical improvement:
• Static test: After surgical ligation, ischemic mouse 
paw retracted. Interdigital spacing (IDS) between 
the first and the 5th toe was measured using Image 
J software. For this, the mouse was placed in a trans-
parent container to visualize from the bottom normal 
and ischemic paws. Measures were taken at day-1 
(baseline), 1, 3, 5, 7, 10, 14, 20 and 28 post surgery. 
Results were expressed as a ratio of IDS ischemic/
control paw. Clinical improvement was testified by 
the gradual recovery of IDS.
• Dynamic test: A semi quantitative assessment of 
impaired use of ischemic limb was performed. Mice 
progressed in a transparent corridor to evaluate 
their walking. The functional scoring was adapted 
from Tarlov‘s [31]: score 0: the mouse does not use 
the paw-score 1: the mouse can rely on the left paw-
score 2: the mouse can use its left paw but claudi-
cates-score 3: normal walking. Measures were taken 
at day-1 (baseline), 1, 3, 5, 7, 10, 14, 20 and 28 post 
surgery.
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The mean and the standard deviation were used per 
group.
Tissue preparation and immunohistological analysis
The gastrocnemius and the semimembranosus mus-
cles [30] right and left of each mouse were harvested at 
day 28. The semimembranosus muscle is localized close 
to the ligation upstream from the cell infusion site. For 
each condition, the muscles were frozen for immunofluo-
rescence assay or fixed in formalin 10% for hematoxylin 
eosin (HE) staining.
For immunofluorescence, tissues were embedded in 
Optimal Cutting temperature (OCT) compound (F/
KMA-0100-00A, MM France, Francheville, France) and 
frozen in liquid nitrogen. Frozen sections of 6-µm thick-
ness were mounted on superfrost slides. Sequentially, 
slides were fixed in cold acetone for 20 min, blocked with 
normal donkey serum (S30, Merck Millipore, St-Quen-
tin-en-Yvelines, France) for 1 h at room temperature and 
incubated with primary antibody at 4 °C overnight. After 
washing three times with PBS, slides were incubated with 
secondary antibody during 1 h at room temperature. The 
vessels were visualized by immunofluorescent staining 
with a first anti-CD31 antibody (ab28364, abcam, Cam-
bridge, United Kingdom) and a second anti alpha-smooth 
muscle actin antibody (αSMA) (ab150129, abcam). 
Secondary fluorochrome-coupled antibodies were 
used (Alexa  Fluor® 568, ab175470, abcam) and (Alexa 
 Fluor® 488, ab21027, abcam). Slides were observed on 
an inverted fluorescence microscope (20× magnifica-
tion Axio Observer Z1, Zeiss Microscopy) piloted by 
Metamorph Software (Roper Scientific). Capillaries and 
arterioles were counted in 5 representative fields from 
3 tissue sections for each muscle using ImageJ software. 
The amount of ischemia-induced angiogenesis and arte-
riogenesis were compared with the non-ischemic muscle. 
Macrophage infiltration were visualized by the same pro-
tocol using an anti-CD68 antibody (ab125212, abcam).
The fixed gastrocnemius and semimembranosus mus-
cles were embedded in paraffin and stained with HE. 
We determine the percentage of muscle fibers with a 
central nucleus. Indeed, these muscle fibers specifically 
indicate muscle regeneration [34, 35]. For this, five fields 
were counted in the central region of the largest cross 
area of gastrocnemius muscle sections. The results were 
expressed as a ratio left muscle/right muscle. All results 
were expressed as mean and standard deviation per 
group.
Real time quantitative polymerase chain reaction (qPCR)
Real time qPCR was performed on right and left har-
vested gastrocnemius muscles of 4 mice (1 mouse for 
each group: vehicle, BMCs, MSCs and S-MSCs) at 
day 28 in order to detect human DNA. The DNA was 
extracted from the muscles with a DNeasy Blood and 
Tissue kit (69504, Qiagen) according to the manufactur-
er’s instructions. Human DNA (n = 2) was used as posi-
tive control. Gastrocnemius muscles of vehicle group and 
non-ischemic controlateral muscles were used as nega-
tive control. The qPCR was performed for human Factor 
V gene (TaqMan SNP genotyping assay, C_11975250_10, 
Thermo Fisher Scientific) and with a TaqMan universal 
PCR master mix (4324018, Thermo Fisher Scientific). We 
checked that human Factor V primers did not hybridize 
with mouse DNA using  BLAST®. Each DNA was ana-
lyzed thrice. The limit of detection of PCR was defined by 
a threshold cycle (Ct) > 35.
Statistical analyses
Quantitative variables were expressed as mean and 
standard deviation per group or as median (Med) and 
range [min–max] or Box and Whiskers plots (Medcalc 
version 7.3 software, https ://www.medca lc.org/). Mann–
Whitney Tests were used to compare differences between 
groups at day 28. Wilcoxon Tests were used to compare 
differences between days in the same group  (Statview®). 
A value of p < 0.05 was considered statistically significant. 
For blood flow analysis, a mixed effect model was per-
formed to assess the relationship between the ischemic/
normal limb ratio and treatment group, the time of the 
measure, adjusted on the value of the ratio at day-1 (base-
line value). Bonferroni method was used for multiple 
comparisons adjustments. The overall survival limb rates 
were estimated by the Kaplan–Meier method. Difference 
between survival curves for each experimental group was 
performed using the log rank test  (GraphPad®).
Results
Patient and BMCs characteristics
BMCs were obtained from 7 different patients presenting 
with CLI and candidates for CT. Patients were represent-
ative of the NO-CLI population in terms of age, associ-
ated cardiovascular risk factors, and current medications 
(Table  1). The severity of the disease was appreciated 
from percutaneous tissue oxygen pressure  (TcPO2) and 
the presence of ulcers.
BMCs were characterized by cell counting and differ-
ential presented in Figs.  2a, 3a and Table  1. HSCs were 
quantified in BMCs by FC: 3.66% ± 1% (Fig.  3a). MSCs 
were quantified in BMCs by a clonogenic assay (CFU-F): 
39 ± 16 MSCs of 1 million nucleated cells (Table 1).
Clinical outcome after 6 and 12 months is presented in 
Table 1.
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MSCs and S‑MSCs in vitro characterization
Cells morphology
Human BM derived MSCs show plastic adherent prop-
erties and have fibroblast-like morphology seen under 
phase contrast microscope (Fig. 2b). S-MSCs were main-
tained in EGM-2 medium from subculture 0 to 2 during 
14  days. S-MSCs presented similar fibroblast-like mor-
phology (Fig.  2c). The S-MSCs’ doubling time was sig-
nificantly shorter in comparison with MSCs (respectively 
4.6 ± 1.6 versus 7.3 ± 1.8 days, p < 0.01).
Transcriptomic profile
In order to differentiate S-MSCs from MSCs, we deter-
mined the transcriptomic profile of both cells. For 
this, the expression of endothelial-lineage genes (vWF, 
PECAM1, VEGF R2, Ve-Cadherin, CXCR4 and VCAM1) 
was examined in MSCs and S-MSCs at day 28 (Fig. 2d). 
cb-ECFCs was used as a endothelial cells (ECs)-control. 
A set of four genes (PECAM1, VEGF R2, Ve-Cadherin 
and CXCR4) was expressed in a comparable way in 
both MSCs and S-MSCs. S-MSCs expressed a signifi-
cant, 44-fold higher level of VCAM1 in comparison with 
MSCs. In contrast, S-MSCs expressed a significantly 
lower level of vWF (4.1-fold lower) in comparison with 
MSCs. In cb-ECFCs, the level of expression of vWF, 
PECAM1, VEGF R2, Ve-Cadherin and CXCR4 was sig-
nificantly higher in comparison with MSCs and S-MSCs.
Phenotype of isolated MSCs and S‑MSCs
The cultured MSCs express on their surface CD105+, 
CD90+ and CD73+, while lacking the expression 
Table 1 Patient characteristics
Quantitative variables are expressed as median or absolute value. Biologic markers measured in 7 NO‑CLI patients on day 0 (baseline) before CT
∅: Patient alive without any major amputation
a Cardioprotective drugs use: antiplatelet therapy (AT), statins (S), angiotensin‑converting enzyme inhibitor (ACEI)
b Other cells: blasts, immature granulocytes and plasma cells
c CFU‑F number/1 × 106 nucleated cells
1 2 3 4 5 6 7
Patients characteristics
 Age (years) 74 57 52 57 74 62 42
 Gender (M: male; F: female) M M M M F M M
 BMI (kg/m2) 27 25 26 32 20 22 21
 Smoker No Past Past Past No Past Current
 Arterial hypertension Yes Yes No No No Yes No
 Hyperlipidemia Yes No Yes No Yes No No
 Diabetes mellitus Yes No Yes No No No No
 Disease characteristics
  TcPO2 (mmHg) 26 30 64 35 45 1 7
  Presence of ulcers No No Yes No No No No
 Cardioprotective drugs  usea AT, ACEI AT, ACEI, S AT, ACEI, S AT, ACEI, S AT AT, S AT, S
BMC characterization
 PLTs (G/L) 746 740 478 590 384 1296 1118
 Total nucleated cells (G/L): 47 60 38 48 50 76 71
 Total MNCs
  Lymphocytes (%) 46 47 39 41 48 46 54
  Monocytes (%) 18 12 28 18 19 14 13
  Erythroblasts and other cells (%)b 10.5 14.3 10.4 19.8 12.7 13.2 14.5
 Mature granulocytes (%) 23 23 18 16 17 23 16
 HSCs (CD34+ cells) (%) 2.5 3.7 4.6 5.2 3.3 3.8 2.5
 MSCsc 42 38 34 58 28 12 60
Placebo or BMCs group BMCs BMCs Placebo Placebo BMCs BMCs Placebo
Clinical outcome at 6 months ∅ ∅ ∅ ∅ ∅ Revascularization 
at day 126
Major ampu‑
tation at day 
114
Clinical outcome at 12 months Revascularization 
at day 332
∅ ∅ ∅ ∅
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of hematopoietic cell markers (CD45−, CD34−, 
CD11b−) and HLA-DR surface marker (Fig.  3b). The 
MSCs were strongly positive for CD146 (MCAM), 
CD140b (PDGF RB), weakly positive for CD140a 
(PDGF RA) and negative for endothelial-specific 
markers (CD31, CD144, VEGF R1, VEGF R2), CD184 
(CXCR4) and CD106 (VCAM1).
S-MSCs grown in EGM-2 during 2 weeks showed the 
classic pattern of MSCs (CD105+, CD90+, CD73+, 
CD45−, CD34−, CD11b− and HLA-DR−) but did not 
express endothelial-specific markers (CD31, CD144, 
VEGF R1, VEGF R2). S-MSCs retained the expression 
of CD90 and acquired the CD106 marker (VCAM1) 
(Fig.  3b). For both markers, a double population of 
cells (with 2 distinct mean fluorescence intensity) was 
observed in all S-MSCs obtained from 7 CLI-patients 
(data not shown).
Taken together, mRNA and protein levels of CD31, 
Ve-Cadherin, VEGF R2 and CXCR4 were not signifi-
cantly increased in S-MSCs. On the contrary, VCAM1 
was up-regulated in S-MSCs.
Cell secretome
Therapeutic potential of undifferentiated MSCs can be 
attributed to their capacity to secrete bioactive factors, 
which may potentially affect both local and systemic 
physiological processes. Thus, we investigated the 
effects of EGM-2 medium on the secretome of S-MSCs 
at day 28 in comparison with MSCs (Table 2). The lev-
els of FGF2, EGF and IGF-1 measured in the S-MSCs 
culture supernates were significantly lower than in 
cell-free EGM-2 culture media. A similar pattern was 
observed in IGF-1 level in the MSCs culture supernates 
in comparison with cell-free CFU-F culture media. 
PDGF-AA, Angio-1, LIF-1, CXCL12, IL-6 and HGF are 
absent from CFU-F and EGM-2 media. Both S-MSCs 
and MSCs secreted HGF and VEGF-A at a comparable 
level. In opposite, S-MSCs secreted significantly higher 
PDGF-AA (22.9-fold higher), Angio-1 (5.6-fold higher), 
LIF-1 (3.1-fold higher) and lower IL-6 (11.8-fold lower) 
than MSCs. Interestingly, S-MSCs completely lost their 
ability to secrete CXCL12.
HMEC-1 suspended in endothelial cell growth 
medium MV were able to form pseudo-tubes in a 
Matrigel assay (Positive control) (Fig. 4a. HMEC-1 did 
Fig. 2 Cells observation and real‑time RT‑PCR analysis. a BMCs morphology in May Grünwald Giemsa staining. b MSCs morphology in phase 
contrast microscopy. c S‑MSCs morphology in phase contrast microscopy. d mRNA expression of six genes of interest were quantified using 
simultaneous real‑time RT‑qPCR experiments in MSCs (black box, n = 7), in S‑MSCs (empty box, n = 7) and cb‑ECFC (grey box, n = 5) used as control. 
x: aberrant distribution values as indicated by Box and Whiskers plots Medcalc version 7.3 software (*p < 0.05 and †p < 0.01)
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not form any pseudo-tubes when suspended in CFU-F 
medium. When suspended in MSCs culture super-
nates, HMEC-1 could form short tubes lacking branch-
ing points and loops. On the contrary, HMEC-1 could 
generate a network of pseudo-tubes when suspended 
in S-MSCs culture supernates. This network was sig-
nificantly more developed when HMEC-1 were sus-
pended in S-MSCs in comparison with MSCs culture 
supernates (p < 0.0002) but also with cell free EGM-2 
medium (p < 0.013).
Taken together, our results indicated that MSCs and 
S-MSCs can be distinguished by their secretome profiles 
in terms of growth factors productions and also in terms 
of functional capacity to form tube-like structures.
Cell functional assay: in vitro tube formation assay
Because MSCs and S-MSCs have a proangiogenic poten-
tial, we looked for their ability to form capillary-like tube 
in an in vitro endothelial tube formation assay. Contrary 
to MRC5 fibroblasts cells line used as negative control, 
Fig. 3 Cells characterization by FC. a BMCs characterization. HSCs (CD34+ cells) analysis was performed by FC according to the ISHAGE reference 
method. b Immunophenotype characterization of isolated MSCs and S‑MSCs. MSCs and S‑MSCs (grey) were stained with the following human 
monoclonal antibodies: CD105 (endoglin), CD90 (Thy‑1), CD73 (5′ nucleotidase), CD34, CD45, CD11b (integrin alpha M), HLA‑DR (human leucocyte 
antigen‑D related), CD146 (MCAM), CD140a (PDGF RA), CD140b (PDGF RB), CD31 (PECAM1), CD144 (Ve‑Cadherin), VEGF R1, VEGF‑R2, CD184 
(CXCR4) and CD106 (VCAM1). The isotype‑matched mouse IgG1‑FITC, IgG1‑PE, IgG1‑PCy5 and IgG1‑ PCy7 were used as negative controls (empty)
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cb-ECFC were constitutively able to form pseudo-tubes 
in a Matrigel assay. MSCs have low ability for 
pseudo-tube formation compared with S-MSCs (p 
value = 0.0008). There was no difference between cb-
ECFC and S-MSCs (Additional file 1: Figure S1).
MSCs and S‑MSCs are effective to restore hindlimb blood 
flow
As MSCs and S-MSCs may have a stronger angiogenic 
potential than BMCs, we compared these cells with vehi-
cle in ischemic Nude mice (Fig.  5). The mouse model 
was validated by the fact that the targeted ischemic ratio 
was obtained and was identical in each group at baseline 
(0.99 ± 0.05) and after surgery (0.31 ± 0.04). Figure  5b 
shows statistical differences between groups. What-
ever the type of cells, their injection was more effective 
to restore leg perfusion as measured by  PeriCam® than 
vehicle (p < 0.0001). MSCs and S-MSCs transplantation 
(Fig. 5b) allowed significant improvement of flow in com-
parison with BMCs [p value (MSCs vs. BMCs) < 0.0033; 
p value (S-MSCs vs. BMCs) < 0.0001]. However, com-
plete flow recovery after BMCs transplantation was not 
achieved at day 28. In comparison, MSCs allowed to fully 
restore the flow at day 20. S-MSCs were more effective 
than BMCs and MSCs and allow achieving full recovery 
at day 14. Figure  5c shows the heterogeneity in terms 
of hindlimb blood flow recovery when BMCs are trans-
planted. In contrast, the response to MSCs and S-MSCs 
was homogeneous regardless the CLI-patient origin.
These results indicate that MSCs and S-MSCs are more 
effective than BMCs (and vehicle) to restore hindlimb 
blood flow.
S‑MSCs improves limb survival in comparison with MSCs
Animal limbs were regularly observed during 28  days 
post operatively to detect necrosis. Ten out of 20 
untreated mice developed necrosis as early as day 3 after 
ligation (Fig. 6). In contrast, in the BMCs group, necrosis 
affected 7 out of 40 (17.5%) mice. The efficacy of BMCs 
injection on limb survival was significant compared 
with vehicle (p < 0.001). In the MSCs group, necrosis 
was observed in 4 out of 35 (11.4%) mice. MSCs signifi-
cantly improved limb salvage in comparison with vehicle 
(p < 0.001) but did not significantly differ from BMCs. In 
contrast, no necrosis was observed after S-MSCs injec-
tion, the necrosis rate being significantly reduced in com-
parison with BMCs but also with MSCs (p < 0.05).
Taken together, these results suggest that S-MSCs have 
the strongest angiogenic potential in comparison with 
BMCs but also MSCs.
MSCs and S‑MSCs injection improves clinical recovery
Cell injection using the three types of cells significantly 
improved clinical recovery in comparison with control 
group (Fig. 7). In all groups, static and dynamic tests were 
well-correlated (Pearson’s test: r = 0.6, p < 0.0001).
In order to appreciate recovery, we measured IDS of 
the ischemic and of the controlateral non-ischemic paw, 
allowing us to calculate an IDS ratio (equal to 1 to achieve 
Table 2 Secretome
A set of ten growth factors [VEGF‑A, EGF, FGF2, IGF‑1, Angio‑1, IL‑6, HGF, PDGF‑AA, LIF, SDF‑1 (or CXCL12)] was measured in the MSCs (n = 7) and S‑MSCs (n = 7) culture 
supernates at day 28 and in CFU‑F and EGM‑2 media
NS not significant, ∅ undetectable
a Cell‑free media
b Comparison of MSCs culture supernates versus S‑MSCs culture supernates
c Comparison after subtraction of basal medium content
CFU‑F medium EGM‑2 medium pb
CFU‑F 
 mediuma
MSCs culture supernates EGM‑2  mediuma S‑MSCs culture supernates
VEGF‑A (pg/mg proteins) ∅ 272 [182–478] 180 464 [288‑627] NSc
FGF2 (pg/mg proteins) ∅ ∅ 101 7 [4–16] 0.003
EGF (pg/mg proteins) ∅ ∅ 5056 1643 [736–3710] 0.003
IGF‑1 (pg/mg proteins) 332 154 [35–308] 826 319 [150–452] 0.003c
PDGF‑AA (pg/mg proteins) ∅ 0.9 [nd–13] ∅ 20 [3–60] 0.003
Angio‑1 (pg/mg proteins) ∅ 159 [91–377] ∅ 899 [371–2234] 0.003
LIF (pg/mg proteins) ∅ 49 [31–82] ∅ 149 [99–283] 0.003
CXCL12 (pg/mg proteins) ∅ 3475 [1418–6987] ∅ ∅ 0.003
IL‑6 (pg/mg proteins) ∅ 741 [479–1202] ∅ 63 [4–127] 0.003
HGF (pg/mg proteins) ∅ 17 [1–44] ∅ 4 [nd–159] NS
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Fig. 4 Angiogenic effect of culture supernates. a MSCs and S‑MSCs culture supernates and cell‑free media (CFU‑F and EGM‑2) were recovered 
at day 28. HMEC‑1 were suspended in endothelial cell growth medium MV (n = 3), in cell‑free CFU‑F medium (n = 3), in cell‑free EGM‑2 medium 
(n = 3), in MSCs culture supernates (obtained from 5 CLI‑MSCs, n = 2 each group), in S‑MSCs culture supernates (obtained from 5 CLI‑S‑MSCs, 
n = 2 each group) and incubated on Matrigel during 24 h. The extend of the network of the capillary‑like tubes was appreciated at 3:30 h. b 
Quantification of the loops number at 3:30 h. c Quantification of total tube length (µm) at 3:30 h. x: aberrant distribution values as indicated by Box 
and Whiskers plots Medcalc version 7.3 software (*p < 0.05, †p < 0.01 and ‡p < 0.001)
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full recovery) (Fig.  7a). BMCs significantly improved 
IDS ratio evaluated at day 28 in comparison with vehi-
cle (IDS ratio BMCs: 0.84 ± 0.15; vehicle: 0.67 ± 0.20, 
p < 0.001). MSCs and S-MSCs were significantly more 
effective than BMCs on IDS ratios at day 28 [IDS ratio 
MSCs: 0.90 ± 0.11; S-MSCs: 0.93 ± 0.09; p (MSCs vs. 
BMCs) < 0.05; p (S-MSCs vs. BMCs) < 0.001; MSCs vs. 
S-MSCs = non-significant) (Fig. 7b).
Cell injection of BMCs, MSCs or S-MSCs significantly 
improved the walking of the ischemic mice as assessed 
by the dynamic test (p < 0.0001) (Fig.  7c). Indeed, in the 
absence of cell infusion, the walking score of the ischemic 
mice progressively improved barely achieving full recovery 
at day 28. On the contrary, full recovery was obtained at 
day 20 after cell infusion, whatever the type of cells used.
S‑MSCs improve angiogenesis and arteriogenesis 
in ischemic muscle
In order to visualize neoangiogenesis after cell infusion, 
capillary density in the semimembranosus (Fig.  8a) and 
Fig. 5 Hindlimb blood flow recovery. a Representative LASCA images show improved perfusion in vehicle‑, BMCs‑, MSCs‑ and S‑MSCs‑ treated 
mice at days 0 after ligation, 3 and 28. Low or no blood perfusion was displayed as dark blue, whereas the highest perfusion was displayed as red. 
b Hindlimb blood flow recovery after femoral artery ligation and BMCs (n = 40), MSCs (n = 35), S‑MSCs (n = 40), or vehicle (n = 20) injection. CT by 
BMCs transplantation (blue) was effective in comparison with vehicle (green) injection for blood flow recovery at day 28 but BMCs did not restore 
completely the blood flow. In contrast MSCs (red) provided complete recovery at day 20 whereas S‑MSCs (violet) were effective to completely 
restore blood flow at day 14. c Hindlimb blood flow recovery after BMCs (approximately 6 mice per patient), MSCs (approximately 6 mice per 
patient) and S‑MSCs (approximately 6 mice per patient) infusion. BMCs were obtained from 7 different CLI‑patients (Table 1) and were considered 
as “gold standard” (*comparison of MSCs group versus BMCs group; #S‑MSCs versus BMCs; ¥S‑MSCs versus MSCs; §BMCs versus vehicle; ΔMSCs versus 
vehicle; ∞S‑MSCs versus vehicle)
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gastrocnemius (Fig.  8b) muscles was assessed by immu-
nofluorescence after CD31 labelling. A ratio was cal-
culated from the fluorescence intensity (CD31+) in the 
ischemic gastrocnemius muscle in comparison with the 
non-ischemic controlateral muscle (Fig.  8c). Capillary 
density was the highest after S-MSCs injection (S-MSCs 
fluorescence ratio: 6.31 ± 0.96; p < 0.05 vs. MSCs) 
(Fig. 8c).
In order to visualize arteriogenesis, we looked at the 
presence of smooth muscle vascular cells associated 
with vessels in the gastrocnemius and semimembrano-
sus muscles (Fig.  8a, b). For this, doubly labelled arteri-
oles (CD31+/αSMA+) were assessed. The analysis of 
the ischemic semimembranosus muscle revealed that 
the CD31 and αSMA-positive vessels had a larger lumen 
diameter than the arterioles observed in controlateral 
normal muscle (Fig. 8a) and that in gastrocnemius mus-
cles (Fig.  8b). In gastrocnemius muscles, the infusion 
of either BMCs, MSCs or S-MSCs did not change the 
aspect of the vessels in comparison with vehicle (Fig. 8b). 
A ratio was calculated from the fluorescence intensity 
(CD31+/αSMA+) in the ischemic gastrocnemius mus-
cle in comparison with the non-ischemic controlateral 
muscle (Fig. 8d). The injection of BMCs did not increase 
the number of CD31 and αSMA-positive vessels in com-
parison with vehicle (Fig. 8d). In contrast, MSCs treated 
mice developed a higher rate of CD31 and αSMA-
positive cells in comparison with BMCs (1.92 ± 0.36 vs. 
1.46 ± 0.53, p < 0.05). Interestingly, S-MSCs treated mice 
presented with the highest CD31 and αSMA-positive 
pattern (S-MSCs fluorescence ratio: 2.38 ± 0.54; p < 0.05 
vs. MSCs). These results suggest that MSCs and S-MSCs 
can induce CD31 and αSMA-positive vessels whereas 
BMCs cannot.
As inflammation is a strong modulator of angiogenesis, 
we evaluated the macrophage infiltration in response to 
cell infusion using a CD68 labeling. We found no differ-
ence in CD68-positive cell counts after the injection of 
either type of cells BMCs, MSCs and S-MSCs. Still, there 
was a difference between either cell type in comparison 
with vehicle (fluorescence ratio BMCs: 8.72 ± 3.06; MSCs: 
9.26 ± 3.37; S-MSCs: 9.71 ± 3.54; vehicle: 12.1 ± 2.18, p 
value for each type of cells vs. vehicle: p < 0.05).
S‑MSCs favor muscle repair after ischemia
A histological analysis of semimembranosus (Fig. 9a) and 
gastrocnemius (Fig. 9b) muscles was performed to visual-
ize ischemic muscle damage and muscle repair after cell 
infusion. For this, the percentage of muscle fibers with 
a central nucleus was determined. Ligation provoked 
ischemic lesions which were still visible at day 28 in both 
muscles. In the ischemic semimembranosus, the muscle 
damage was comparable whatever the type of infused 
cells (Fig. 9a). In contrast, in the ischemic gastrocnemius, 
there was a glaring difference depending on the type of 
infused cells (Fig. 9b). BMCs failed to favor gastrocnemius 
repair (37 ± 18% expressed as a percentage of total muscle 
fibers), in comparison with vehicle (33 ± 20%) (Fig.  9c). 
Fig. 6 Limb survival. a S‑MSCs provide complete limb salvage in comparison with MSCs and BMCs. b In comparison with vehicle (n = 20), BMCs 
(n = 40) provided better limb salvage (p < 0.001). There was no difference between BMCs and MSCs (n = 35) treatment. S‑MSCs (n = 40) were the 
most protective compared to BMCs and MSCs (p < 0.05)
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MSCs did increase the rate of myofibers with central 
nuclei (46 ± 15%), in comparison with vehicle (p < 0.01).
The effect of S-MSCs on muscle repair (74 ± 20%) was 
significantly stronger than vehicle (p < 0.001) and BMCs 
(p < 0.001). Interestingly, S-MSCs were more effective 
than MSCs on ischemic muscle repair (p < 0.01). This 
indicates that S-MSCs may favor gastrocnemius repair 
more efficiently than MSCs after ischemia.
Absence on human nucleus at the end of the experiment
At day 28, a real time qPCR was performed on DNA 
extracted from gastrocnemius muscles in order to detect 
human nucleus. Human DNA was used as positive con-
trol (Ct of human Factor V gene = 24.1 ± 0.1). Gastroc-
nemius muscles of vehicle group and non-ischemic 
controlateral muscles did not contain any detect-
able human DNA (Ct of human Factor V gene > 35). No 
human DNA (Ct of human Factor V gene > 35) was found 
in ischemic and injected gastrocnemius muscles, what-
ever the type of cells (BMCs, MSCs or S-MSCs). This 
suggests the absence of any residual human cell at the 
end of the experiment.
Discussion
Among innovative therapies, CT is a good candidate to 
treat patients with severe PAD. BMCs are considered as 
“gold standard” in CLI-CT because it was used by the 
founder trial [4]. In spite of encouraging clinical studies, 
the efficacy of CT remains controversial [7, 8]. This may 
be partially explained by the heterogeneity of autologous 
Fig. 7 Functional tests (static and dynamic). a, b Static tests: MSCs and S‑MSCs were significantly more effective than BMCs and vehicle to 
improve IDS. MSCs (red) and S‑MSCs (violet) provided significantly higher ratios at day 28 in comparison with BMCs (blue). There was no difference 
between the MSCs and S‑MSCs groups. c Dynamic test: S‑MSCs, MSCs and BMCs were effective to restore a normal walk in comparison with vehicle 
[*comparison of MSCs group (n = 35) versus BMCs group (n = 40); #S‑MSCs (n = 40) versus BMCs; ¥S‑MSCs versus MSCs; §BMCs versus vehicle 
(n = 20); ΔMSCs versus vehicle; ∞S‑MSCs versus vehicle]
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BMCs [11]. In such BMCs, HSCs are extremely rare and 
may not support proangiogenic properties of BMCs [5]. 
Still, these autologous BMCs may be the source of other 
types of proangiogenic stem cells. Indeed undifferenti-
ated MSCs were obtained from BMCs CLI-patients as 
previously described [11, 29, 36].
Fig. 8 Neovessels visualization with CD31 and αSMA labelling. CD31 + staining (red) detects both angiogenic capillaries and arterioles. αSMA+ 
(green) detects arterioles. a Visualization of capillaries and arterioles in the semimembranosus in normal and ischemic legs. b Visualization of 
capillaries and arterioles in the gastrocnemius in normal and ischemic legs. c Angiogenesis analysis: fluorescence intensity ratio (CD31+ labelling) 
in the ischemic gastrocnemius in comparison with controlateral muscle. d Arteriogenesis analysis: Fluorescence intensity ratio (αSMA+/CD31+ 
labelling) in the ischemic gastrocnemius in comparison with controlateral muscle (*comparison of MSCs group versus BMCs group; #S‑MSCs versus 
BMCs; ¥S‑MSCs versus MSCs; §BMCs versus vehicle; ΔMSCs versus vehicle; ∞S‑MSCs versus vehicle)
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MSCs are well-recognized for their high proliferation 
and differentiation potential. MSCs support a significant 
paracrine effect through the secretion of proangiogenic 
cytokines which provide anti-apoptotic effects and stim-
ulate revascularization [15].
In the first step of our study, we confirmed the presence 
of MSCs in CLI-BMCs. We next evaluated if the culture 
of MSCs in a medium enriched in endothelial growth 
factors (EGM-2) could improve the proangiogenic 
properties of MSCs that we named S-MSCs. S-MSCs 
that we obtained from CLI-patients showed a morphol-
ogy which was indistinguishable from MSCs obtained in 
CFU-F medium. However, S-MSCs’ doubling time was 
shorter for when compared with MSCs’, in agreement 
with published data [21, 25, 37].
We next characterized S-MSCs in FC and observed 
that these cells did not express endothelial markers 
(CD31, Ve-Cadherin, VEGF R1 and VEGF R2). Using 
Fig. 9 Evaluation of muscle repair. a Histological analysis of semimembranosus muscle in normal and ischemic leg. b Histological analysis of 
gastrocnemius muscle in normal and ischemic leg. c Evaluation of muscle repair: percentage of muscle fibers with a central nucleus quantified in 
the ischemic gastrocnemius in comparison with its controlateral muscle (*comparison of MSCs group versus BMCs group; #S‑MSCs versus BMCs; 
¥S‑MSCs versus MSCs; §BMCs versus vehicle; ΔMSCs versus vehicle; ∞S‑MSCs versus vehicle)
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other sources of MSCs derived from umbilical cord 
blood [25, 26], adipose tissue [22, 23, 27] or BM, but 
from healthy donors [21], an endothelial differentia-
tion of MSCs was reported when cultured in EGM-2 
medium [37]. Oswald et al. was the first to report that 
a VEGF induction gave rise to the endothelial differen-
tiation of MSCs expression classical endothelial mark-
ers but not CD31 [38]. Tancharoen et  al. also, showed 
that S-MSCs expressed endothelial markers including 
CD31 but with a much lower level than HUVECs [39]. 
In agreement with our data, other published studies 
on WJ-MSCs [32], BM-MSCs [40] or diabetic patients 
ADSCs [41], stated that endothelial cell growth supple-
ment alone could not per se induce the expression of 
molecular markers of ECs. This illustrates the difficulty 
encountered to define such cells when cultured in dif-
ferent conditions. The term of “endothelial-like cells” 
has been employed by some authors [21, 32, 40, 42] in 
spite of a high heterogeneity in both culture conditions 
and MSCs origin. Interestingly, it was suggested that 
shear stress could be a major parameter for endothelial 
differentiation [40].
Our data show that MSCs and S-MSCs express com-
parable proteomic and transcriptomic profiles except 
for VCAM1 which is significantly higher in S-MSCs. 
VCAM1 mediated the interaction of MSCs with ECs, 
which is essential for MSCs homing [43]. This expression 
of VCAM1 was previously reported in S-MSCs obtained 
in the presence of VEGF-A [38]. A role of EGF, which is 
present in EGM-2 medium, has been shown to increase 
VCAM1 and MSCs adhesion to ECs [44].
To further characterize S-MSCs, we analyzed their 
secretion capacity. For this, we quantified a set of ten 
growth factors in S-MSCs culture supernates in com-
parison with MSCs. Our data indicate major differ-
ences between these two types of cells: in comparison 
with MSCs, S-MSCs produce high levels of PDGF-AA, 
Angio-1 and LIF whereas the secretion of pro-inflamma-
tory IL-6 is significantly lower. CXCL12 is not secreted 
by S-MSCs whereas it is found at high concentration in 
the MSCs supernatant. The loss of capacity of S-MSCs 
to secrete CXCL12 could be the consequence of EGM-2 
induction. Using a supplementation with platelet-rich 
plasma, which contains PDGF, TGFβ1, FGF2, IGF-1, 
VEGF and EGF (some of them being also present in 
EGM-2 medium), Goedecke et  al, have reported a loss 
of CXCL12 secretion associated with a defect in HSCs 
migration [45]. The analysis of S-MSCs supernatants 
indicated the diminution in the concentration of FGF2, 
EGF and IGF-1 present in the EGM-2 medium. This 
may be the consequence of a consumption or could 
be explained by the endocytosis of a ligand-receptor 
complex.
In order to further characterize the secretome, we 
evaluated the capacity of supernates to induce tube-like 
structures from HMEC-1. We observed that S-MSCs 
culture supernates had the strongest ability to induce 
tube-like structures. This is in agreement with the results 
of growth factor quantification showing that S-MSCs 
supernates contain higher concentrations of proangio-
genic factors. Taken together, these results suggest that 
the secretome analysis allows to differentiate S-MSCs 
from MSCs. A further issue would be to elucidate the 
potency of each growth factor present in conditioning 
media. Furthermore, the existence of possible autocrine 
mechanisms has to be considered.
Our study shows that S-MSCs can be functionally dis-
tinguished from MSCs by their stronger capacity to form 
pseudo-tubes in  vitro. This confirms most reports hav-
ing used EGM-2 induction [21–23, 25, 40, 41, 46]. How-
ever, Choi et  al, raised the point that MSCs are able to 
form tube-like structures in Matrigel but the observation 
of these pseudo-tubes by electron microscopy revealed 
the absence of lumen [32]. Although commonly used, 
Matrigel cannot be considered as a specific angiogenic 
assay [47].
It was therefore mandatory to evaluate in  vivo, the 
proangiogenic potential of MSCs and S-MSCs. In a 
well-established mouse model of HLIM [30], our results 
clearly indicate that MSCs from CLI-patients completely 
restore blood flow (primary endpoint) in comparison 
with BMCs that we considered as the “gold standard”. 
Such results are in agreement with those obtained by 
Iwase et al, who concluded that BM-MSCs were superior 
to BMCs in promoting neovascularization [48]. The limit 
of this study was that BM-MSCs were obtained from 
young rats. Indeed, it has been shown that age could 
impair stem cell properties [9]. In the context of CLI, this 
alteration could be further increased in case of associ-
ated risk factors [20]. In contrast, MSCs obtained from 
CLI-patients conserve proangiogenic properties through 
a paracrine mechanism [15, 29, 49]. This may be at least 
partly explained by the fact that, BM-MSCs from CLI-
patient have a similar secretome profile compared to that 
of healthy MSCs [29, 50]. In agreement with this hypoth-
esis, Smadja et al, 2012 and Gremmels et al, 2014 showed, 
in a HLIM model, that MSCs from CLI-patients had a 
comparable proangiogenic potential to MSCs isolated 
from age matched patients free of any cardiovascular dis-
ease [29, 36].
To our knowledge, this is the first report to establish the 
property of S-MSCs obtained from CLI-patients infused 
in HLIM model. Interestingly, S-MSCs restored com-
pletely blood flow and earlier than MSCs. The infusion of 
BMCs led to a highly heterogeneous response in terms of 
extend and kinetics of blood flow recovery. This fits with 
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the heterogeneity of BMCs in terms of cellular content. 
In contrast, the infusion of MSCs and S-MSCs restored 
blood flow in a homogeneous manner. The selection and 
amplification in culture may allow to obtain a consist-
ent favorable response to infusion, and this whatever the 
patient’s clinical status.
We further demonstrated that MSCs and S-MSCs 
could improve clinical recovery as well as limb salvage. 
In agreement with Iwase et al, MSCs were more effective 
than BMCs to save limb [48]. Our results indicate that 
S-MSCs were also more effective than MSCs.
Interestingly, the analysis of the gastrocnemius muscle 
clearly shows that S-MSCs not only enhance neovascu-
larization but also favor the development of vascular 
muscle cells suggesting the formation of mature and sta-
ble capillaries [51]. Indeed, arteriogenesis is more capable 
of restoring tissue blood supply than angiogenesis [52]. 
Collateral vessels have the capacity to carry a larger vol-
ume of blood than sprouting capillary networks [53].
In contrast, the analysis of the semimembranosus mus-
cle indicates an enlargement of the vessels and limited 
ischemia. This is explained by the anatomic situation of 
this muscle which is located proximally to the ligation 
site. It was reported that, following a femoral artery liga-
tion, an arteriogenic process is initiated by the increase 
of blood pressure in the pre-existing collaterals that cir-
cumvent the obstruction and can supply blood flow to 
the distal tissue [54]. In contrast, gastrocnemius muscle 
being downstream from the ligation site is more sensitive 
to ischemia and therefore prone to undergo a process of 
angiogenesis. In this respect, our results clearly show the 
favorable effect of cell infusion. This effect may be more 
the consequence of a paracrine effect considering the 
high potential of secretion of such cells. The proangio-
genic effect is unlikely related to endothelial differentia-
tion of infused cells since no human DNA was detected 
at the end of the experiment. Previous studies have illus-
trated the rapid disappearance of infused cells [55, 56].
A major advantage of S-MSCs may be their capacity 
to improve skeletal muscle repair after ischemia. This 
effect could explain the efficacy of S-MSCs to reduce the 
amputation rate. To evaluate muscle repair, we quantified 
myofibers with central nucleus location. Indeed, muscle 
regeneration is characterized by the activation of myo-
genic cells which leads to the formation of new myofib-
ers. These fibers are recognized by a centrally located 
myonucleus [34, 35, 57, 58].
MSCs have been evaluated in 13 clinical trials in the 
last decade [17–19, 59–66] and have included a total 
population of 216 MSCs-treated patients. These studies 
have established the safety of such cells [18, 67], which 
may be at least partly explained by their immunomodula-
tory properties [16, 68, 69]. Clinical trial results were in 
favor of efficacy, one randomized clinical trial concluding 
that MSCs were more effective than BMCs [17].
Our study pointed out the importance of the secretome. 
This should be extended to the analysis of secretome con-
tent including extracellular vesicles, exosomes, micro-
RNAs, mRNAs, long non-coding RNAs, circular RNAs 
which may have an interest in CLI-therapeutics [15, 70].
Conclusions
MSCs have been suggested to be a promising alternative 
source for ischemic diseases [42].
The present study shows that S-MSCs can be obtained 
from the BM of patients presenting severe PAD. S-MSCs 
can restore blood flow as efficiently as MSCs and more 
potently than BMCs. A major issue of CT in PAD is to 
provide a fully stable and mature vascular network. In 
this regard, S-MSCs are promising candidates as they 
restore flow in CLI and provide muscle repair. Many sug-
gested improvements can be proposed to produce these 
cells for CLI-cell therapy. MSC secretome may also be of 
therapeutic value.
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Additional file 1: Figure S1. Cell functional assay: in vitro tube formation 
assay. a MRC5 (n = 5), cb‑ECFC (n = 4), MSCs (n = 7) and S‑MSCs (n = 7) 
were incubated on Matrigel. The extend of the network of the capillary‑
like tubes was appreciated at the time of maximal network. b S‑MSCs 
form more cord‑like structures than MSCs (cb‑ECFC are used as positive 
control and MRC5 as negative control). The extend of the network of the 
capillary‑like tubes was appreciated at the time of maximal network by 
the quantification of the loops number. (†p < 0.01 and ‡p < 0.001).
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